Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.

[1]  B. O'neill,et al.  Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. , 2018, Blood.

[2]  J. Copland,et al.  Immune checkpoint inhibition by anti‐PDCD1 (anti‐PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model , 2018, British journal of haematology.

[3]  L. Ysebaert,et al.  Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. , 2018, Blood.

[4]  J. Warner,et al.  Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies , 2018, European journal of haematology.

[5]  K. Beccaria,et al.  Ibrutinib brain distribution: a preclinical study , 2018, Cancer Chemotherapy and Pharmacology.

[6]  Jeffrey A Jones,et al.  Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center , 2017 .

[7]  L. Staudt,et al.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. , 2017, Cancer cell.

[8]  M. Shipp,et al.  CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA , 2017 .

[9]  K. Hoang-Xuan,et al.  Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network , 2016 .

[10]  H. Tun,et al.  Preclinical Evaluation of Ibrutinib for Central Nervous System Lymphoma , 2016 .

[11]  J. Golmard,et al.  ISOLD: A New Highly Sensitive Interleukin Score for Intraocular Lymphoma Diagnosis. , 2016, Ophthalmology.

[12]  Roland Schmitz,et al.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.

[13]  Andrew J. Dunford,et al.  Targetable genetic features of primary testicular and primary central nervous system lymphomas. , 2014, Blood.

[14]  K. Hoang-Xuan,et al.  Mutational analysis of primary central nervous system lymphoma , 2014, Oncotarget.

[15]  K. Hoang-Xuan,et al.  Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas , 2012, Clinical Cancer Research.

[16]  Paul Shinn,et al.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.

[17]  R. Spang,et al.  Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell , 2008, Leukemia.

[18]  S. Baudet,et al.  IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. , 2007, Investigative ophthalmology & visual science.

[19]  J. Armitage,et al.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Schaller,et al.  Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. , 2004, Blood.

[21]  D. Ellison,et al.  V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. , 1999, Blood.

[22]  C. Brennan,et al.  Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. , 2017, Cancer discovery.

[23]  K. Hoang-Xuan,et al.  Clinical/Scientific Notes , 2011, Neurology.

[24]  R. Advani,et al.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Hoang-Xuan,et al.  A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. , 2006, Blood.

[26]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.